Apixaban

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Retrieved on: 
Tuesday, April 9, 2024
ODD, Warfarin, Thrombosis, VADS, Risk, Vitamin K antagonist, New Drug Application, Patient, Apixaban, Stroke, Anticoagulant, Splenic infarction, Death, Therapy, Bleeding, LVAD, FDA, VKA, Pharmaceutical industry

PONTE VEDRA, Fla., April 9, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, announced today that the United States Food and Drug Administration (FDA) has granted tecarfarin Orphan Drug Designation (ODD) for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist device (LVAD), right ventricular assist device (RVAD), collectively known as ventricular assist devices (VADs), biventricular assist device, and total artificial heart).

Key Points: 
  • "This second orphan drug designation highlights the expanded need for tecarfarin where existing anticoagulation therapies are inadequate," said Quang Pham, Founder, Chairman and Chief Executive Officer of Cadrenal Therapeutics.
  • "We are dedicated to advancing tecarfarin through clinical development options as swiftly as possible."
  • Since its adoption in 1983, the Orphan Drug Act has helped countless individuals living with these conditions gain access to life-enhancing and life-saving therapies.
  • The designation is made to promote safe and efficacious products for the treatment of rare conditions.

epocrates Delivered Clinical and Commercial Innovation in 2023, Building a Foundation for Scale, Impact, and Engagement for its 1 million+ Physician User Base

Retrieved on: 
Tuesday, February 27, 2024
Apps, Applications, Technology, Nursing, Hospitals, Clinical Trials, Practice Management, Managed Care, Health, Pharmaceutical, CME, Behavior, Algorithm, BSN, Apixaban, Atorvastatin, Amlodipine, Intelligence, RN, Patient, University, Infection

The home screen and newsfeed are core experiences for epocrates users, and the company made several updates to bring educational and actionable information more front and center for clinicians.

Key Points: 
  • The home screen and newsfeed are core experiences for epocrates users, and the company made several updates to bring educational and actionable information more front and center for clinicians.
  • These updates include a new home page newsfeed on epocrates web, calls to action on newsfeed articles, and enhanced interactive functionality.
  • These enhancements serve to streamline clinicians’ experience while navigating the platform and offer information that may assist with patients they see in the future.
  • “The ability to purchase enterprise-wide subscriptions was something we'd been asking for and are pleased to see that it's now an option."

Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
Assistive technology, Conference, NASDAQ Biotechnology Index, Anticoagulant, Partnership, Metabolism, Risk, Death, Biotechnology, Warfarin, Bleeding, Antiphospholipid syndrome, APS, Atrial fibrillation, Phạm, Therapy, ESKD, Stroke, Splenic infarction, Kidney disease, Ventricular fibrillation, Patient, Apixaban, Pharmaceutical industry

"Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."

Key Points: 
  • "Tecarfarin provides a more stable anticoagulation than warfarin due to its metabolism, thereby decreasing the risk of stroke and bleeding."
  • To arrange a meeting with management, please contact your Biotech Showcase representative or Lytham Partners at [email protected] .
  • The ceremony will feature healthcare companies within the Nasdaq Biotechnology Index, highlighting them as companies pioneering the future.
  • The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

Retrieved on: 
Monday, September 18, 2023
Endocrinology, University, Atlas Venture, Diabetes, Internal medicine, CSO, Intarcia Therapeutics, Cardiovascular disease, Atlas, Head, Research, CMO, Bristol Myers Squibb, Apixaban, Harvard Medical School, Metabolism, Washington University School of Medicine, Faculty, Growth, BMS, Therapy, Pharmaceutical industry, Medical device, Verve, Medicine

Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO.

Key Points: 
  • Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO.
  • “We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company,” said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve.
  • Verve’s tremendous progress over the last five years has been made possible by Andrew’s significant contributions in his joint role.
  • Under his leadership, several new medicines achieved successful marketing authorization, including Eliquis® (apixaban), Farxiga® (dapagliflozin), Onglyza® (saxagliptin) and Myalept® (metreleptin).

Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023

Retrieved on: 
Friday, August 25, 2023
Biotechnology, General Health, Health, Pharmaceutical, Cardiology, Ochsner Health System, Bleeding, Pfizer, Senior, Trial of the century, Stroke, FACP, PFE, FACC, RVT, NVAF, European Society of Cardiology, Bristol Myers Squibb, PSM, Medicine, Pharmacy, Data mart, Congress, Anticoagulant, Hospital medicine, MMM, Patient, Risk, Causality, Rivaroxaban, Confidence interval, Clutch (eggs), BMS, ESC, Safety, Pharmaceutical industry, Medical imaging, Apixaban, MB, Ventricular fibrillation, ATHENS, MD

There were 167,868 Eliquis initiators and 65,888 rivaroxaban initiators who met study criteria.

Key Points: 
  • There were 167,868 Eliquis initiators and 65,888 rivaroxaban initiators who met study criteria.
  • It is important to note that anticoagulants, including Eliquis, increase the risk of bleeding and can cause serious, potentially fatal bleeding.
  • Additionally, reasons for switching are not known and sample size for those who switched is much lower than those who continued treatment.
  • Due to these limitations, real-world data analyses are not used as evidence to validate the efficacy and/or safety of a treatment.

Now available from Aniara Diagnostica DP-Filter® For Removal of DOACs from Plasma Specimens

Retrieved on: 
Thursday, August 24, 2023
Anticoagulant, Use, WEST, Dabigatran, Edoxaban, Multimedia, DOAC, Apixaban, Plasma, DP, Diagnosis, Rivaroxaban, Filtration, Research

WEST CHESTER, Ohio, Aug. 24, 2023 /PRNewswire-PRWeb/ -- Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today's highest standards for product quality and cost-efficient delivery.

Key Points: 
  • WEST CHESTER, Ohio, Aug. 24, 2023 /PRNewswire-PRWeb/ -- Aniara Diagnostica, a multi-national distributor of diagnostic and research agents, as well as screening tools, has strengthened its commitment to meeting today's highest standards for product quality and cost-efficient delivery.
  • The study of blood samples containing DOACs is challenging and may lead to false results.
  • The DP-Filter® is effective in filtering DOAC from citrated plasma providing anticoagulant-free plasma that can be used for testing.
  • The entire Aniara product line is available for purchase at http://www.aniara.com .

Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023

Retrieved on: 
Monday, August 21, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Bristol Myers Squibb, Apixaban, Senior, ESC Congress, Atrial fibrillation, NVAF, European Society of Cardiology, Research, SOC, BMY, Congress, MD, Standard of care, Patient, Risk, Circulatory system, Rivaroxaban, ESC, NYSE, LTE, Safety, Ventricular fibrillation, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place in-person and virtually August 25-28, 2023.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research reinforcing the strength of its robust cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place in-person and virtually August 25-28, 2023.
  • The Bristol Myers Squibb-Pfizer Alliance will also share an observational retrospective real-world study on the clinical impact of switching or continuation of Eliquis® (apixaban) or rivaroxaban among patients with non-valvular atrial fibrillation (NVAF).
  • “This year’s ESC Congress provides the opportunity to present new data spanning our cardiovascular portfolio, reinforcing our ambition of bringing innovative and life-changing medicines to patients living with cardiovascular diseases,” said Roland Chen, MD, Senior Vice President and Head of Cardiovascular & Neuroscience Development, Global Drug Development.
  • Select Bristol Myers Squibb and Bristol Myers Squibb-Pfizer Alliance studies at ESC Congress 2023 include:

CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM)

Retrieved on: 
Wednesday, March 22, 2023
Blood pressure, Radboud University Nijmegen, Fresenius Medical Care, Cytokine adsorbing column, Shock, Capillary leak syndrome, Research, Septic shock, Failure mode and effects analysis, Marketing, Professional corporation, Apixaban, Sepsis, Blood, Intensive care medicine, Patient, Physician, Acute respiratory distress syndrome, Hospital, BMS, Cytokine, Post-cardiac arrest syndrome, Vaccine, Pharmaceutical industry, Pfizer

Prof. Peter Pickkers (Radboud University Nijmegen, The Netherlands) will focus on the ability of CytoSorb to reduce circulating cytokines during systemic inflammation in a robust controlled human study.

Key Points: 
  • Prof. Peter Pickkers (Radboud University Nijmegen, The Netherlands) will focus on the ability of CytoSorb to reduce circulating cytokines during systemic inflammation in a robust controlled human study.
  • CytoSorb is being increasingly used as a ‘go-to’ therapy option for critically ill patients suffering from a broad range of life-threatening illnesses, especially septic shock.
  • Treating physicians and health care professionals around the world have directly experienced the beneficial impact of our therapy on their patients.
  • We are excited to reconnect with key opinion leaders, customers, and partners from the global medical community to share our latest experiences and clinical studies with them.

CytoSorbents Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Thursday, March 9, 2023
Transfer, Currency, Hospital, ICU, Security, Advertising, Clinical trial, Secretary of State of New Jersey, Note 2, Autoimmune disease, Bed, Comparison, Consultant, Term, EUA, Research, Patient, FDA, Public expenditure, Growth, Patent, Apixaban, ATM, Travel, Marketing, BMS, COVID-19, Insurance, Bank statement, Bridge bank, Sale, Cytokine adsorbing column, South German Customs Union, Pharmaceutical industry, Security (finance), Cryptocurrency, Financial services, Euro, Pfizer

PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported financial and operating results for the quarter and year ended December 31, 2022 and provides its 2023 outlook.

Key Points: 
  • For the years ended December 31, 2022 and 2021, cost of revenue was approximately $13,956,000 and $11,047,000, respectively, an increase of approximately $2,909,000.
  • Product cost of revenues increased approximately $698,000 during the year ended December 31, 2022 as compared to the year ended December 31, 2021.
  • Product gross margins were approximately 70% for the year ended December 31, 2022 and approximately 80% for the year ended December 31, 2021.
  • The 2022 loss is directly related to the decrease of the exchange rate of the Euro as of December 31, 2022 as compared to December 31, 2021.

epocrates Celebrates Sizable 2022 Growth, Driven by New Design, Tools, and Guidelines to Improve the Clinician Experience

Retrieved on: 
Thursday, March 2, 2023
Health, Apps, Applications, Technology, Health Technology, Mobile, Wireless, Pharmaceutical, Biotechnology, United States Department of Health and Human Services, Growth, News, RSV, Yoy, COVID-19, CDC, Mpox, Enterovirus, Apixaban, Infection, HIV, Amlodipine, DHHS, Atorvastatin, Mobile phone, Pharmaceutical industry

Notably, epocrates redesigned its mobile app to further improve the clinician experience, streamlining access to the many tools clinicians rely on at the point of care and beyond.

Key Points: 
  • Notably, epocrates redesigned its mobile app to further improve the clinician experience, streamlining access to the many tools clinicians rely on at the point of care and beyond.
  • Since the redesign in May 2022, news views have increased 64% and interaction check usage has increased 59% pointing to major growth in both epocrates’ clinician engagement and usage.
  • As the nation’s clinician shortage intensifies, the remaining healthcare workforce is busier than ever and facing growing caseloads to keep up with patient demand.
  • In addition to supporting busy clinicians with a more user-friendly mobile app, epocrates also released several updates to its decision support tools and enhanced content in 2022.